2021, doi:10.1016/j.amsu.2021.102917 Sun, Xiaojin et al
Bioassay measuring GLP-1 receptor activation, though this is non-specific
Expanding horizons through discovery In parallel with OX472 development, and supported by the AmorphOX technology, the discovery work is advancing to evaluate semaglutide and other GLP-1 agonists via additional administration routes and across multiple indications
Treatment is guided by the same Utah-based MD, with personalized dosing, side-effect support, and long-term weight management focused on safe, sustainable weight loss
Partner with us to incorporate this transformative ingredient into your product line and meet the growing demand for science-driven skincare solutions
Andreatta M, Karosiene E, Rasmussen M, Stryhn A, Buus S, Nielsen M